# Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00687674** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** sorafenib tosylate
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00687674
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687674, "Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00687674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*